-
Product Insights
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Drugs In Development, 2023’, provides an overview of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Anthrax – Drugs In Development, 2023
Global Markets Direct’s, ‘Anthrax - Drugs In Development, 2023’, provides an overview of the Anthrax pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Yellow Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Yellow Fever - Drugs In Development, 2023’, provides an overview of the Yellow Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Yellow Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Leishmaniasis (Kala-Azar) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) - Drugs In Development, 2023’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PHI-101 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PHI-101 in Refractory Acute Myeloid Leukemia Drug Details:PHI-101 is under development for the treatment of relapsed...
-
Sector Analysis
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Company Profile
iBio Inc – Company Profile
iBio Inc (iBio) is a preclinical-stage biotechnology company that utilizes artificial intelligence (AI) for the development of precision antibodies. Its pipeline products include IBIO-101 for the indication of solid tumors. The company's other oncology and autoimmune programs comprise Trop-2 x CD3, -MUC16, EGFRvIII and PD-1 for the treatment of multiple solid tumors, including breast, lung, colorectal and pancreatic cancers, glioblastoma, rheumatoid arthritis and other inflammatory diseases. iBio platform includes its patented epitope-steering AI engine, StableHu technology, a machine learning-based antibody-optimizing,...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Drugs Market Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation therapy....
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...